Related Experiment Video
Updated: Sep 7, 2025

Intratracheal Instillation of Stem Cells in Term Neonatal Rats
Published on: May 4, 2020
Irrational prescription of surfactant replacement therapy in neonatal respiratory distress
Nader Jahanmehr1,2, Reyhane Izadi1, Abbas Habibolahi3
1Health Economics, Management and Policy Department, Virtual School of Medical Education & Management, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Insights
Irrational surfactant prescriptions for neonates with respiratory distress in Iran were high, with 31.47% of cases showing errors in drug selection, dose, or timing. Interventions are needed to improve neonatal care and reduce these preventable medication errors.
Area of Science:
- Neonatal Medicine
- Pharmacology
- Public Health
Background:
- Respiratory distress is a primary cause of neonatal mortality.
- Surfactant therapy has significantly improved outcomes for respiratory failure in neonates.
- Increased surfactant prescription in Iran may be linked to irrational prescribing practices.
Purpose of the Study:
- To determine the rate of irrational surfactant prescription for neonates with respiratory distress in Iran.
- To analyze prescription patterns against established surfactant guidelines.
Main Methods:
- A retrospective, cross-sectional descriptive study was conducted.
- Data from 846 neonates receiving surfactant therapy in Iran in 2018 were analyzed.
- Irrational prescribing was assessed based on drug selection, dose, and timing indices.
Main Results:
- Irrational drug selection occurred in 14.30% of cases.
- Irrational dosing was observed in 27.42% of cases.
- A total of 31.47% of neonates received irrational surfactant prescriptions.
Conclusions:
- The high rate of irrational surfactant prescriptions necessitates immediate attention from healthcare providers and policymakers.
- Educational interventions and computer-based alerts are recommended to reduce prescription errors.
- Improving surfactant prescribing practices is crucial for enhancing neonatal health outcomes.
Purpose:
Respiratory distress is known as one of the leading causes of neonatal death. In recent decades, surfactant therapy has revolutionized respiratory failure. Since the implementation of the health system reform plan as well as the allocation of new financial resources for health system in Iran, the rate of irrational prescription has increased and prescription of surfactant for neonates, has raised unexpectedly, which is thought to be due to irrational prescriptions partly. The present study aimed to determine the rate of irrational prescription of surfactant for neonates with respiratory distress.
Methods:
This research was a cross-sectional descriptive study, which was conducted retrospectively. In the current study, determining the rate of irrational prescription was done in terms of the surfactant prescription guideline. Finally, the medical data of 846 neonates who underwent surfactant therapy in Iran in 2018, were extracted from the information system of the Ministry of Health and the neonatal medical records.
Results:
The results show that drug selection index, dose index, and time index were irrational for 14.30%, 27.42%, and 1.06% of neonates, respectively. Moreover, the total index of drug prescription, which is a combination of the above-mentioned three components, was found to be irrational for 31.47% of neonates.
Conclusions:
The results of the present study are considered as a warning to providers and decision makers in the field of neonatal health to reduce irrational prescriptions of surfactant for neonates. This study suggests the use of educational interventions in order to reduce irrational prescriptions due to drug selection as well as the use of computer alert approaches in order to reduce irrational prescriptions due to wrong dose.
More Related Videos
06:22Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS
Published on: April 7, 2021
04:21A Minimally Invasive Method for Intratracheal Instillation of Drugs in Neonatal Rodents to Treat Lung Disease
Published on: August 4, 2021
Related Concept Videos
Breathing
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Pulmonary Cycle: Exhalation
Acute Respiratory Failure-III
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include: